[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573142":3},{"organization":4,"armGroups":7,"interventions":31,"overallOfficials":41,"centralContacts":46,"locations":52,"responsibleParty":103,"collaborators":10,"id":105,"slug":106,"hasResults":107,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":113,"sex":114,"minAge":115,"maxAge":116,"enrollmentInfo":117,"targetDuration":10,"studyType":120,"phases":10,"briefSummary":121,"conditions":122,"keywords":10,"overallStatus":55,"whyStopped":10,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":137},{"fullName":5,"class":6},"Fecundis Lab SL","OTHER",[8,15,19,23,27],{"label":9,"type":10,"description":11,"interventionNames":12},"Normozoospermic",null,"Semen samples with normal sperm parameters as defined by the World Health Organization guidelines (e.g., normal sperm concentration, motility, and morphology).",[13,14],"Device: Standard sperm preparation","Device: HyperSperm",{"label":16,"type":10,"description":17,"interventionNames":18},"Teratozoospermic","Semen samples with abnormal sperm morphology, where the percentage of morphologically normal sperm is below the threshold set by the World Health Organization (i.e., 4%).",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Asthenozoospermic","Semen samples characterized by reduced sperm motility, where the percentage of progressive motile sperm is below the threshold set by the World Health Organization (i.e., 32%).",[13,14],{"label":24,"type":10,"description":25,"interventionNames":26},"Oligozoospermic","Semen samples with a low sperm concentration, below the World Health Organization reference value (i.e., less than 15 million sperm per milliliter).",[13,14],{"label":28,"type":10,"description":29,"interventionNames":30},"Cryopreserved semen","Semen samples that have been preserved through freezing and stored at ultra-low temperatures.",[13,14],[32,37],{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":10},"DEVICE","Standard sperm preparation","Sperm samples in the control group will undergo traditional processing",[20,28,9,24,16],{"type":33,"name":38,"description":39,"armGroupLabels":40,"otherNames":10},"HyperSperm","Sperm samples in the experimental group will undergo product-specific processing",[20,28,9,24,16],[42],{"name":43,"affiliation":44,"role":45},"Mariona Rius Mas, PhD","Fertty","PRINCIPAL_INVESTIGATOR",[47],{"name":48,"role":49,"phone":50,"phoneExt":10,"email":51},"Matias Gomez Elias, PhD","CONTACT","+34624174355","mgomezelias@fecundis.com",[53,71,81,92],{"facility":54,"status":55,"city":56,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"Eugin Barcelona","RECRUITING","Barcelona","08006","Spain","ES",{"type":61,"coordinates":62},"Point",[63,64],2.15899,41.38879,{"lat":64,"lon":63},[67],{"name":68,"role":49,"phone":69,"phoneExt":10,"email":70},"Rafael Lafuente","+34933221122","rlafuente@eugin.es",{"facility":44,"status":55,"city":56,"state":56,"zip":72,"country":58,"countryCode":59,"cosmosGeoPoint":73,"geoPoint":75,"contacts":76},"08010",{"type":61,"coordinates":74},[63,64],{"lat":64,"lon":63},[77],{"name":78,"role":49,"phone":79,"phoneExt":10,"email":80},"Mariona Rius Mas","+34937378190","mariona.rius@fertty.com",{"facility":82,"status":55,"city":56,"state":56,"zip":83,"country":58,"countryCode":59,"cosmosGeoPoint":84,"geoPoint":86,"contacts":87},"CIRH","08017",{"type":61,"coordinates":85},[63,64],{"lat":64,"lon":63},[88],{"name":89,"role":49,"phone":90,"phoneExt":10,"email":91},"Karinna Lattes","+34932806535","klattes@cirh.es",{"facility":93,"status":55,"city":56,"state":56,"zip":94,"country":58,"countryCode":59,"cosmosGeoPoint":95,"geoPoint":97,"contacts":98},"Natuvitro","08029",{"type":61,"coordinates":96},[63,64],{"lat":64,"lon":63},[99],{"name":100,"role":49,"phone":101,"phoneExt":10,"email":102},"Raul Noblom Artigues","+34936555888","raul@natuvitro.com",{"type":104,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100573142","efficacy-and-safety-of-a-new-sperm-capacitation-method-100573142",false,"NCT06742437","Efficacy and Safety of a New Sperm Capacitation Method","Efficacy and Safety of a New Sperm Capacitation Method: a Prospective in Vitro Study on Semen Samples","HyperSperm01","Inclusion Criteria:\n\n* Ability to provide a semen sample via masturbation\n\nExclusion Criteria:\n\n* Current diagnosis of a sexually transmitted infection (STI)\n* Previous diagnosis of hepatitis A, B, C, D, or HIV\n* Prior participation in this study\n* Participation in a clinical trial involving an intervention within the last 3 months",true,"MALE","18 Years","60 Years",{"count":118,"type":119},300,"ESTIMATED","OBSERVATIONAL","Prospective, multicenter research study with a split-sample design on semen samples, without intervention, to evaluate the efficacy and safety of HyperSperm, a new sperm capacitation method, in 300 semen samples with various characteristics and abnormalities, in an in vitro study over 12 months.",[123,124,125,126,127],"Reproductive Issues","Male Infertility","Asthenozoospermia","Oligozoospermia","Teratozoospermia","2026-02-24",{"date":130,"type":131},"2026-02-27","ACTUAL",{"date":133,"type":131},"2025-01-14",{"date":135,"type":119},"2026-06",{"name":5,"class":6},4]